Immunoglobulin Fab Fragments
- Name
- Immunoglobulin Fab Fragments
- Accession Number
- DBCAT001914
- Description
Univalent antigen-binding fragments composed of one entire IMMUNOGLOBULIN LIGHT CHAIN and the amino terminal end of one of the IMMUNOGLOBULIN HEAVY CHAINS from the hinge region, linked to each other by disulfide bonds. Fab contains the IMMUNOGLOBULIN VARIABLE REGIONS, which are part of the antigen-binding site, and the first IMMUNOGLOBULIN CONSTANT REGIONS. This fragment can be obtained by digestion of immunoglobulins with the proteolytic enzyme PAPAIN.
- Drugs
Drug Drug Description Caplacizumab A von Willebrand factor (vWF)-directed antibody fragment used to treat acquired thrombotic thrombocytopenic purpura (aTTP). Certolizumab pegol A tumor necrosis factor (TNF) blocker used to treat a variety of autoimmune and autoinflammatory conditions like Crohn's disease, rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, and plaque psoriasis. Abciximab A monoclonal anti-glycoprotein IIb/IIIa receptor antibody used to prevent thrombosis during percutaneous coronary intervention. Pexelizumab For the treatment of inflammation during cardiac surgery. Gancotamab Gancotamab is under investigation in clinical trial NCT02213744 (MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients). Vobarilizumab Vobarilizumab is under investigation in clinical trial NCT02101073 (ALX-0061 Phase I Bioavailability Study in Healthy Volunteers). Gontivimab Gontivimab is under investigation in clinical trial NCT03468829 (Efficacy and Safety of ALX-0171 in Adult Hematopoietic Stem Cell Transplant (HSCT) Recipients Who Present With Respiratory Syncytial Virus (RSV) Infection). - Drugs & Drug Targets